Ileana Bortolomai

1.4k total citations
20 papers, 586 citations indexed

About

Ileana Bortolomai is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ileana Bortolomai has authored 20 papers receiving a total of 586 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Ileana Bortolomai's work include Ovarian cancer diagnosis and treatment (6 papers), HER2/EGFR in Cancer Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Ileana Bortolomai is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), HER2/EGFR in Cancer Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Ileana Bortolomai collaborates with scholars based in Italy, United States and United Kingdom. Ileana Bortolomai's co-authors include Emiliano Cocco, Peter E. Schwartz, Thomas Rutherford, Alessandro D. Santin, Stefania Bellone, Dana M. Roque, Elena Ratner, Masoud Azodi, Natália Buza and Salvatore Lopez and has published in prestigious journals such as PLoS ONE, Cancer and Cancer Research.

In The Last Decade

Ileana Bortolomai

20 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ileana Bortolomai Italy	17	283	246	122	84	67	20	586
Daniel S. Kong United States	9	341 1.2×	224 0.9×	93 0.8×	110 1.3×	64 1.0×	14	568
Marta Bellone Italy	11	147 0.5×	243 1.0×	69 0.6×	45 0.5×	76 1.1×	18	446
I.-M. Shih United States	11	343 1.2×	182 0.7×	232 1.9×	105 1.3×	177 2.6×	15	768
Andreas Brunner Austria	13	164 0.6×	159 0.6×	81 0.7×	68 0.8×	28 0.4×	20	499
Alfred Schauer Germany	14	309 1.1×	213 0.9×	133 1.1×	99 1.2×	44 0.7×	22	683
Manu P. Kumar United States	9	434 1.5×	206 0.8×	258 2.1×	139 1.7×	99 1.5×	10	797
Micaela Morgado United States	9	169 0.6×	366 1.5×	252 2.1×	84 1.0×	30 0.4×	12	641
Zhangyan Guo China	13	441 1.6×	312 1.3×	269 2.2×	317 3.8×	35 0.5×	18	917
Magdalena Potoczek United States	11	321 1.1×	162 0.7×	60 0.5×	161 1.9×	17 0.3×	16	589
S.V. Kupriyanov Russia	4	255 0.9×	81 0.3×	108 0.9×	65 0.8×	39 0.6×	9	484

Countries citing papers authored by Ileana Bortolomai

Since Specialization

Citations

This map shows the geographic impact of Ileana Bortolomai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ileana Bortolomai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ileana Bortolomai more than expected).

Fields of papers citing papers by Ileana Bortolomai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ileana Bortolomai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ileana Bortolomai. The network helps show where Ileana Bortolomai may publish in the future.

Co-authorship network of co-authors of Ileana Bortolomai

This figure shows the co-authorship network connecting the top 25 collaborators of Ileana Bortolomai. A scholar is included among the top collaborators of Ileana Bortolomai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ileana Bortolomai. Ileana Bortolomai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russo, Fabio, Eliana Ruggiero, Francesca Sanvito, et al.. (2022). Editing T cell repertoire by thymic epithelial cell-directed gene transfer abrogates risk of type 1 diabetes development. Molecular Therapy — Methods & Clinical Development. 25. 508–519. 4 indexed citations

Ferrua, Francesca, Elena Fontana, Stefano Beretta, et al.. (2021). Premature Senescence and Increased Oxidative Stress in the Thymus of Down Syndrome Patients. Frontiers in Immunology. 12. 669893–669893. 17 indexed citations

Castiello, Maria Carmina, Marita Bosticardo, Enrica Calzoni, et al.. (2020). Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency. Journal of Allergy and Clinical Immunology. 147(1). 309–320.e6. 26 indexed citations

Bortolomai, Ileana, Francesca Ferrua, Elena Fontana, et al.. (2019). Thymic Epithelium Abnormalities in DiGeorge and Down Syndrome Patients Contribute to Dysregulation in T Cell Development. Frontiers in Immunology. 10. 447–447. 64 indexed citations

Bortolomai, Ileana, Monica Sandri, Elena Draghici, et al.. (2019). Gene Modification and Three-Dimensional Scaffolds as Novel Tools to Allow the Use of Postnatal Thymic Epithelial Cells for Thymus Regeneration Approaches. Stem Cells Translational Medicine. 8(10). 1107–1122. 29 indexed citations

Cecco, Loris De, Francesco Raspagliesi, Maria Luisa Carcangiu, et al.. (2018). Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. Journal of Experimental & Clinical Cancer Research. 37(1). 146–146. 21 indexed citations

Schena, Francesca, Ciro Menale, Emanuela Caci, et al.. (2017). Murine Rankl−/− Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector. Stem Cells. 35(5). 1365–1377. 24 indexed citations

Cecchetti, Serena, Ileana Bortolomai, Renata Ferri, et al.. (2015). Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma. PLoS ONE. 10(9). e0136120–e0136120. 18 indexed citations

Schwab, Carlton L., Dana M. Roque, Diana P. English, et al.. (2015). Afatinib, an irreversible ErbB family blocker, demonstrates remarkable activity against HER2 amplified uterine serous endometrial cancer in vitro and in vivo. Gynecologic Oncology. 136(2). 397–398. 1 indexed citations

10.

English, Diana P., Stefania Bellone, Carlton L. Schwab, et al.. (2014). Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 121(3). 403–412. 20 indexed citations

11.

Schwab, Carlton L., Stefania Bellone, Diana P. English, et al.. (2014). Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. British Journal of Cancer. 111(9). 1750–1756. 21 indexed citations

12.

English, Diana P., Stefania Bellone, Carlton L. Schwab, et al.. (2014). T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Medicine. 3(5). 1256–1265. 34 indexed citations

13.

Lopez, Salvatore, Emiliano Cocco, Stefania Bellone, et al.. (2014). Abstract 4498: Afatinib, an irreversible ErbB family inhibitor, demonstrates activity against HER2 mutated cervical cancer in vitro. Cancer Research. 74(19_Supplement). 4498–4498. 1 indexed citations

14.

English, Diana P., Dana M. Roque, Luisa Carrara, et al.. (2013). HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecologic Oncology. 131(3). 753–758. 35 indexed citations

15.

Roque, Dana M., Stefania Bellone, Diana P. English, et al.. (2013). Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer. 119(14). 2582–2592. 42 indexed citations

16.

English, Diana P., Stefania Bellone, Emiliano Cocco, et al.. (2013). Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). American Journal of Obstetrics and Gynecology. 209(5). 465.e1–465.e9. 30 indexed citations

17.

Roque, Dana M., Natália Buza, Stefania Bellone, et al.. (2013). Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis. 31(1). 101–110. 38 indexed citations

18.

Bellone, Stefania, Dana M. Roque, Emiliano Cocco, et al.. (2012). Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal of Cancer. 106(9). 1543–1550. 45 indexed citations

19.

Bortolomai, Ileana, Silvana Canevari, Loris De Cecco, et al.. (2010). Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle. 9(6). 1194–1206. 66 indexed citations

20.

Sabbioneda, Simone, Ileana Bortolomai, Michele Giannattasio, Paolo Plevani, & Marco Muzi-Falconi. (2006). Yeast Rev1 is cell cycle regulated, phosphorylated in response to DNA damage and its binding to chromosomes is dependent upon MEC1. DNA repair. 6(1). 121–127. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact